1. Boyle P, Veronesi U, Tubiana M et al. European School of Oncology advisory report to the European Commission for the “Europe Against Cancer Programme” European Code Against Cancer. Eur J Cancer 1995; 31A: 1395–1405.

2. Cook PJ, Doll R, Fellingham SA. A mathematical model for the age distribution of cancer in man. Int J Cancer 1969; 4: 93–112.

3. Boyle P, Severi G. Epidemiology of prostate cancer chemoprevention.
Eur Urol 1999; 35: 370–376.

4. Parkin DM, Whelan S, Ferlay J et al. (eds). Cancer incidence in five continents, vol VIII. IARC Scientific Publication No. 155. Lyon, France:International Agency for Research on Cancer 2002.

5. Doll R, Fraumeni JF, Muir CS. Cancer Trends. Oxford, UK: Oxford University Press 1994.

6. Haenszel W, Kurihara M. Studies of Japanese migrants I. Mortality from cancer and other diseases among Japanese in the United States. J Natl Cancer Inst 1968; 40: 43–68.

7. Grulich AE, McCredie M, Coates M. Cancer incidence in Asian migrants to New South Wales, Australia. Br J Cancer 1995; 71: 400–408.

8. Cairns J. Cancer, Science and Society. Cold Spring Harbor, NY: Cold Spring Harbor Press 1980.

9. Doll R, Peto R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst 1981; 66: 1191–1308.

10. Boyle P. Testicular cancer: the challenge for cancer control. Lancet Oncol (Submitted).

11. Boyle P, Soukop M, Scully C et al. Improving prognosis of Hodgkin’s disease in Scotland. Eur J Cancer Clin Oncol 1988; 24: 229–234.

12. Early Breast Cancer Trialists’ Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992; 339: 71–85.

13. Cunningham D, Findlay M. The chemotherapy of colon cancer can nolonger be ignored. Eur J Cancer 1993; 29: 2077–2079.

14. IARC. Non-ionizing radiation, part 1: static and extremely low frequency (ELF) electric and magnetic fields. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, vol 80. Lyon, France: International Agency for Research on Cancer 2002.

15. Boice JD Jr, McLaughlin JK. Epidemiologic studies of cellular telephones and cancer risk. SSI report 2002:16. Stockholm, Sweden: Swedish Radiation Protection Authority 2002.

16. Hennekens CH, Buring JE, Manson JE et al. Lack of effect on long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular diseases. N Engl J Med 1996; 334: 1145–1149.

17. Lee IM, Cook N, Manson JE, Hennekens H. £]-carotene supplementation and incidence of cancer and cardiovascular disease: the Women’s Health study. J Natl Cancer Inst 1999; 91: 2102–2106.

18. The Alpha-Tocopherol, Beta Carotene Prevention Study Group. The effectof vitamin E and beta carotene on the incidence of lung cancer and othercancers in male smoker. N Engl J Med 1994; 330: 1029–1035.

19. Omen GS, Goodman GE, Thornquist MD et al. Effect of combination of beta carotene and vitamin A on lung cancer and cardiovascular diseases. N Engl J Med, 1996; 334: 1150–1155.

20. Blot WJ, Li JY, Taylor PR et al. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst 1993; 85: 1483–1492.

21. Correa P, Fonthan ETH, Bravo JC et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. J Natl Cancer Inst 2000; 92: 1881–1888.

22. Greenberg ER, Baron JA, Stukel TA et al. A clinical trial of beta carotene to prevent basal-cell and squamous-cell cancers of the skin. The Skin Cancer Prevention Study Group. N Engl J Med 1990; 323: 789–795.

23. Clark LC, Combs GF, Turnbull BW et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutrition Prevention of Cancer Study Group. JAMA 1996; 276: 1957–1963.

24. Li JY,Taylor PR, Li B et al. Nutrition intervention trials in Linxian, China: multiple vitamin/mineral supplementation, cancer incidence, and diseasespecific mortality among adults with esophageal dysplasia. J Natl Cancer Inst 1993; 85: 1492–1498. 1000

25. McKeown-Eyssen GE, Bright-See E, Bruce WR et al. A randomized trial of a low fat high fibre diet in the recurrence of colorectal polyps. Toronto Polyp Prevention Group. J Clin Epidemiol 1994; 47: 525–536.

26. Schatzkin A, Lanza E, Corle D et al. Lack of effect of a low-fat, high-fibre diet on the recurrence of colorectal adenomas. N Engl J Med 2000; 342: 1149–1155.

27. MacLennan R, Macrae F, Bain C et al. Randomized trial of intake of fat, fiber, and £]-carotene to prevent colorectal adenomas. The Australian Polyp Prevention Project. J Natl Cancer Inst 1995; 87: 1760–1766.

28. Alberts DS, Martinez ME, Roe DJ et al. Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. N Engl J Med 2000; 342: 1156–1162.

29. Bonithon-Kopp C, Kronborg O, Giacosa A et al. Calcium and fibre supplementation in prevention of colorectal adenoma recurrence: a randomised intervention study. European Cancer Prevention Organisation Study Group. Lancet 2000; 356: 1300–1306.

30. Baron JA, Beach M, Mandel JS et al. Calcium supplements for the prevention of colorectal adenomas. Calcium Polyp Prevention Study Group. N Engl J Med 1999; 340: 101–107.

31. Hofstad B, Almendingen K, Vatn M et al. Growth and recurrence of colorectal polyps: a double-blind 3-year intervention with calcium and antioxidants. Digestion 1998; 59: 148–156.

32. Giardiello FM, Hamilton SR, Krush AJ et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993; 328: 1313–1316.

33. Steinbach G, Lynch PM, Phillips RK et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342: 1946–1952.

34. Ladenheim J, Garcia G, Titzer D et al. Effect of sulindac on sporadic colonic polyps. Gastroenterology 1995; 108: 1083–1087.

35. Calaluce R, Earnest DL, Heddens D et al. Effects of piroxicam on prostaglandin E2 levels in rectal mucosa of adenomatous polyp patients: a randomized phase IIb trial. Cancer Epidemiol Biomarkers Prev 2000; 9: 1287–1292.

36. Thun MJ, Henley J, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002; 94: 252–266.

37. Veronesi U, Maisonneuve P, Costa A et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Lancet 1998; 352: 93–97.

38. Powles TJ, Eeles R, Ashley S et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998; 352: 98–101.

39. Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90: 1371–1387.

40. IBIS investigators. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 2002;360: 817–824.

41. Cauley JA, Norton L, Lippman ME et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 2001; 65: 125–134.

42. Cuzick J, Powles T, Veronesi U et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003; 361: 296–300.

43. IARC. Hormonal contraception and post-menopausal hormonal therapy. IARC Monographs on the Evaluation of the Carcinogenic Risks to Humans, vol 72. Lyon, France: International Agency for Research onCancer 1999.